For the Inventor, By the Inventor

Enter assignee name

Innovent Biologics (Suzhou) Co., Ltd.

USPTO Granted Patents = 20

Trademarks = 13

Forward Citations = 7

Loading Chart...

Loading Chart...

47 inventors (with patents filed for the assignee):

Junjian Liu (11 out of 12 patents)

Xiaolin Liu (8 out of 8 patents)

Andy Tsun (7 out of 7 patents)

4. Xiaoniu Miao (5 out of 6 patents)

5. Cheng Chen (4 out of 6 patents)

6. Bingliang Chen (3 out of 4 patents)

7. Hemanta Baruah (3 out of 11 patents)

8. Weifeng Huang (3 out of 3 patents)

9. Shuaixiang Zhou (3 out of 3 patents)

10. Xinzhen Shi (2 out of 2 patents)

11. Dandan Liu (2 out of 2 patents)

12. Jianfeng Zhou (2 out of 2 patents)

13. Guang Hu (2 out of 2 patents)

14. Yongkun Yang (2 out of 2 patents)

15. Guangrong Meng (2 out of 2 patents)

20 patents: Sort by Forward Citations

1. 12269855 - Interleukin-2 and use thereof (2025-04-08),

2. 12098195 - Anti-IL-23p19 antibody and use thereof in treating diseases (2024-09-24),

3. 11807663 - Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof (2023-11-07),

4. 11753471 - Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing same (2023-09-12),

5. 11746148 - Antibody molecules comprising a single-domain antigen-binding site and Fab fragments (2023-09-05),

6. 11732044 - Anti-LAG-3 antibody and use thereof (2023-08-22),

7. 11708417 - Miniaturized antibody of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR), and polymer and use thereof (2023-07-25),

8. 11655296 - Anti-CD47 antibody and use thereof (2023-05-23),

9. 11498972 - Anti-OX40 antibody and use thereof (2022-11-15),

10. 11485795 - Anti-PCSK9 antibody and use thereof (2022-11-01),

11. 11370837 - Anti-TIGIT antibody and use thereof (2022-06-28),

12. 11352424 - Anti-Tim-3 antibodies for combination with anti-PD-1 antibodies (2022-06-07),

13. 11292836 - Anti-CD47 antibodies and uses thereof (2022-04-05),

14. 11274153 - Anti-PD-L1 nanobody and use thereof (2022-03-15),

15. 11266690 - Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof (2022-03-08),

Innovent Biologics (Suzhou) Co., Ltd. is a leading biopharmaceutical company in China focused on discovering, developing, manufacturing, and commercializing high-quality biologics for the treatment of major diseases. The company is dedicated to transforming patients' lives through innovative therapies. With a robust pipeline of biologics in development, Innovent aims to address unmet medical needs in oncology, autoimmune, and metabolic diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

20 Patents

#34 in Jiangsu

#1,315 in China

#30,364 in the World

Innovent Biologics (Suzhou) Co., Ltd.

Forward Citations = 7

47 inventors:

Junjian Liu (11 out of 12 patents)

Xiaolin Liu (8 out of 8 patents)

Andy Tsun (7 out of 7 patents)

4. Xiaoniu Miao (5 out of 6 patents)

5. Cheng Chen (4 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…